Wealthspire Advisors (New York)’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Buy	+6,497	New	+$216K	﹤0.01%	1133
2025 Q4	–	Sell	-210	Closed	-$4.24K	–	2710
2025 Q3	$4.24K	Buy	+210	New	+$3.69K	﹤0.01%	2385
2023 Q3	–	Sell	-140,123	Closed	-$1.06M	–	618
2023 Q2	$1.06M	Sell	140,123 -10,000	-7%	-$81.1K	0.02%	243
2023 Q1	$1.33M	Sell	150,123 -2,351	-2%	-$23.2K	0.02%	202
2022 Q4	$1.39M	Sell	152,474 -67,649	-31%	-$590K	0.03%	201
2022 Q3	$1.78M	Buy	220,123 +70,000	+47%	+$619K	0.04%	157
2022 Q2	$1.13M	Sell	150,123 -170,000	-53%	-$1.48M	0.02%	203
2022 Q1	$3.01M	Buy	320,123 +35,253	+12%	+$294K	0.07%	99
2021 Q4	$2.28M	Buy	284,870 +142,519	+100%	+$1.29M	0.05%	135
2021 Q3	$1.39M	Buy	+142,351	New	+$1.33M	0.03%	208
2019 Q1	–	Sell	-16	Closed	–	–	706
2018 Q4	$0	Buy	+16	New	+$328	﹤0.01%	916

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Wealthspire Advisors (New York)'s TEVA Position: Q2 2026 in Review

Wealthspire Advisors (New York) opened a new position in Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026: 6,497 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1133 among its holdings. This is a return to the name: Wealthspire Advisors (New York) previously reported a position in TEVA as recently as Q3 2025.

Wealthspire Advisors (New York) first reported a position in TEVA in Q4 2018 and has held it in 11 quarters since. The position peaked at $3.01M in Q1 2022. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Wealthspire Advisors (New York) held 6,497 shares of Teva Pharmaceutical Industries Limited worth $220K as of Q2 2026.
Teva Pharmaceutical Industries Limited was a new Wealthspire Advisors (New York) position in Q2 2026.
Teva Pharmaceutical Industries Limited made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1133 holding.
Wealthspire Advisors (New York) first reported a position in Teva Pharmaceutical Industries Limited in Q4 2018 and has held it in 11 quarters since.
Wealthspire Advisors (New York)'s Teva Pharmaceutical Industries Limited position peaked at $3.01M in Q1 2022.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.